Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Josep M. Tabernero

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2495-8139; OpenAlex author ID A5015190461. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
111
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 4 papers

Papers 22

  1. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. Co-author DOI 10.1002/cam4.5893↗
  2. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  3. Clinical and genomic characterisation of early-onset pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113338↗
  4. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  5. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  6. The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF-MEK1/2-ERK1/2 Pathway. Co-author DOI 10.1158/0008-5472.can-20-4263↗
  7. Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001563↗
  8. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Last author DOI 10.1007/s00280-019-03807-4↗
  9. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cance… First author DOI 10.1007/s00280-019-03931-1↗
  10. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Last author DOI 10.1038/s41416-018-0246-z↗
  11. Pancreatic cancer heterogeneity and response to Mek inhibition. Co-author DOI 10.1038/onc.2017.174↗
  12. Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasi… Co-author DOI 10.1097/mpa.0000000000000867↗
  13. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. Co-author DOI 10.2147/ott.s124097↗
  14. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.185↗
  15. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitab… Co-author DOI 10.1093/annonc/mdw006↗
  16. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Co-author DOI 10.1093/jnci/dju413↗
  17. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis o… Co-author DOI 10.1158/1078-0432.ccr-14-3222↗
  18. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with meta… Co-author DOI 10.1634/theoncologist.2014-0394↗
  19. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Co-author DOI 10.1007/s12094-014-1177-7↗
  20. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  21. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗
  22. SEOM clinical guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1007/s12094-011-0693-y↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 9 shared papers, 2014–2023 · strength 0.78
  2. Michele Reni · 7 shared papers, 2013–2023 · strength 0.55
  3. David Goldstein · 6 shared papers, 2015–2023 · strength 0.42
  4. Daniel D. Von Hoff · 7 shared papers, 2013–2020 · strength 0.35
  5. Eric Van Cutsem · 3 shared papers, 2013–2023 · strength 0.27
  6. Elena Gabriela Chiorean · 5 shared papers, 2013–2020 · strength 0.27
  7. Do‐Youn Oh · 2 shared papers, 2021–2023 · strength 0.24
  8. Rocio García‐Carbonero · 3 shared papers, 2018–2021 · strength 0.24
  9. Karim Adnane Benhadji · 3 shared papers, 2018–2019 · strength 0.23
  10. Davide Melisi · 3 shared papers, 2018–2019 · strength 0.23
  11. Ana P. Vivancos · 2 shared papers, 2017–2023 · strength 0.22
  12. Ramesh K. Ramanathan · 4 shared papers, 2013–2020 · strength 0.22
  13. Kim Pedersen · 2 shared papers, 2017–2021 · strength 0.18
  14. Faiz Bilal Espejo · 2 shared papers, 2017–2021 · strength 0.18
  15. Joaquı́n Arribas · 2 shared papers, 2017–2021 · strength 0.18
  16. Alfredo Romano · 4 shared papers, 2015–2016 · strength 0.18
  17. Florian Castet · 1 shared paper, 2023 · strength 0.17
  18. Volker Kunzmann · 3 shared papers, 2015–2017 · strength 0.16
  19. Werner Scheithauer · 3 shared papers, 2015–2017 · strength 0.16
  20. Ivelina Gueorguieva · 2 shared papers, 2018–2019 · strength 0.16
  21. Emile E. Voest · 1 shared paper, 2023 · strength 0.16
  22. Luca Gianni · 1 shared paper, 2023 · strength 0.16
  23. Giuseppe Viale · 1 shared paper, 2023 · strength 0.16
  24. Elisabeth G.E. de Vries · 1 shared paper, 2023 · strength 0.16
  25. Hye Jin Choi · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.